Reference:

Abate, N. et al. (2002) ‘Sex Steroid Hormones, Upper Body Obesity, and Insulin Resistance’, The Journal of Clinical Endocrinology & Metabolism, 87(10), pp. 4522–4527. doi: 10.1210/jc.2002-020567.

Abou-Seif, M. A. M. and Youssef, A.-A. (2001) ‘Oxidative Stress and Male IGF-1, Gonadotropin and Related Hormones in Diabetic Patients’, Clinical Chemistry and Laboratory Medicine, 39(7). doi: 10.1515/CCLM.2001.099.

Achemlal, L. et al. (2005) ‘Bone metabolism in male patients with type 2 diabetes’, Clinical Rheumatology, 24(5), pp. 493–496. doi: 10.1007/s10067-004-1070-9.

Alberti, K. G. M. et al. (2005) ‘The metabolic syndrome—a new worldwide definition’, The Lancet, 366(9491), pp. 1059–1062. doi: 10.1016/S0140-6736(05)67402-8.

Andersson, B. et al. (1994) ‘Testosterone concentrations in women and men with NIDDM.’, Diabetes care, 17(5), pp. 405–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8062607 (Accessed: 16 June 2018).

Andò, S., Rubens, R. and Rottiers, R. (1984) ‘Androgen plasma levels in male diabetics’, Journal of Endocrinological Investigation, 7(1), pp. 21–24. doi: 10.1007/BF03348370.

Barrett-Connor, E. (1992) ‘Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus.’, Annals of internal medicine, 117(10), pp. 807–11. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1416554 (Accessed: 16 June 2018).

Barrett-Connor, E., Khaw, K. T. and Yen, S. S. (1990a) ‘Endogenous sex hormone levels in older adult men with diabetes mellitus.’, American journal of epidemiology, 132(5), pp. 895–901. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2239904 (Accessed: 16 June 2018).

Barrett-Connor, E., Khaw, K. T. and Yen, S. S. (1990b) ‘Endogenous sex hormone levels in older adult men with diabetes mellitus.’, American journal of epidemiology, 132(5), pp. 895–901. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2239904 (Accessed: 21 June 2018).

Basu, R. et al. (2007) ‘Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men.’, Diabetes care. American Diabetes Association, 30(8), pp. 1972–8. doi: 10.2337/dc07-0359.

Basu, R. et al. (2007) ‘Effect of 2 Years of Testosterone Replacement on Insulin Secretion, Insulin Action, Glucose Effectiveness, Hepatic Insulin Clearance, and Postprandial Glucose Turnover in Elderly Men’, Diabetes Care, 30(8), pp. 1972–1978. doi: 10.2337/dc07-0359.

Bhasin, S. et al. (2011a) ‘Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts’, The Journal of Clinical Endocrinology & Metabolism, 96(8), pp. 2430–2439. doi: 10.1210/jc.2010-3012.

Bhasin, S. et al. (2011b) ‘Reference Ranges for Testosterone in Men Generated Using Liquid Chromatography Tandem Mass Spectrometry in a Community-Based Sample of Healthy Nonobese Young Men in the Framingham Heart Study and Applied to Three Geographically Distinct Cohorts’, The Journal of Clinical Endocrinology & Metabolism, 96(8), pp. 2430–2439. doi: 10.1210/jc.2010-3012.

Blouin, K., Boivin, A. and Tchernof, A. (2008) ‘Androgens and body fat distribution’, The Journal of Steroid Biochemistry and Molecular Biology, 108(3–5), pp. 272–280. doi: 10.1016/j.jsbmb.2007.09.001.

Brüning, J. C. et al. (2000) ‘Role of brain insulin receptor in control of body weight and reproduction.’, Science (New York, N.Y.), 289(5487), pp. 2122–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11000114 (Accessed: 11 June 2018).

Buvat, J. et al. (2010) ‘Endocrine Aspects of Male Sexual Dysfunctions’, The Journal of Sexual Medicine, 7(4), pp. 1627–1656. doi: 10.1111/j.1743-6109.2010.01780.x.

Camacho, E. M. et al. (2013) ‘Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study’, European Journal of Endocrinology, 168(3), pp. 445–455. doi: 10.1530/EJE-12-0890.

Chandel, A. et al. (2008) ‘Testosterone concentration in young patients with diabetes.’, Diabetes care. American Diabetes Association, 31(10), pp. 2013–7. doi: 10.2337/dc08-0851.

Chearskul, S. et al. (2000) ‘Study of plasma hormones and lipids in healthy elderly Thais compared to patients with chronic diseases: diabetes mellitus, essential hypertension and coronary heart disease.’, Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 83(3), pp. 266–77. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10808681 (Accessed: 16 June 2018).

Chen, R. Y. T., Wittert, G. A. and Andrews, G. R. (2006) ‘Relative androgen deficiency in relation to obesity and metabolic status in older men’, Diabetes, Obesity and Metabolism, 8(4), pp. 429–435. doi: 10.1111/j.1463-1326.2005.00532.x.

Cohen, P. G. (1999) ‘The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt--a major factor in the genesis of morbid obesity.’, Medical hypotheses. Elsevier, 52(1), pp. 49–51. doi: 10.1054/mehy.1997.0624.

Cohen, P. G. (1999) ‘The hypogonadal–obesity cycle: role of aromatase in modulating the testosterone–estradiol shunt – a major factor in the genesis of morbid obesity’, Medical Hypotheses, 52(1), pp. 49–51. doi: 10.1054/mehy.1997.0624.

Corona, G. et al. (2010) ‘The Effect of Statin Therapy on Testosterone Levels in Subjects Consulting for Erectile Dysfunction’, The Journal of Sexual Medicine, 7(4), pp. 1547–1556. doi: 10.1111/j.1743-6109.2009.01698.x.

Corona, G. and Maggi, M. (2010) ‘The role of testosterone in erectile dysfunction’, Nature Reviews Urology, 7(1), pp. 46–56. doi: 10.1038/nrurol.2009.235.

Corrales, J. J. et al. (2004) ‘Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control.’, Metabolism: clinical and experimental, 53(5), pp. 666–72. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15131775 (Accessed: 16 June 2018).

Crawford, E. D. et al. (2007) ‘The association of time of day and serum testosterone concentration in a large screening population’, BJU International, 100(3), pp. 509–513. doi: 10.1111/j.1464-410X.2007.07022.x.

Dandona, P. and Dhindsa, S. (2011a) ‘Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity.’, The Journal of clinical endocrinology and metabolism. The Endocrine Society, 96(9), pp. 2643–51. doi: 10.1210/jc.2010-2724.

Dandona, P. and Dhindsa, S. (2011b) ‘Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity.’, The Journal of clinical endocrinology and metabolism. The Endocrine Society, 96(9), pp. 2643–51. doi: 10.1210/jc.2010-2724.

Daubresse, J. C. et al. (1978) ‘Pituitary-testicular axis in diabetic men with and without sexual impotence.’, Diabete & metabolisme, 4(4), pp. 233–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/365649 (Accessed: 16 June 2018).

Defay, R. et al. (1998) ‘Hormonal status and NIDDM in the European and Melanesian populations of New Caledonia: a case-control study. The CALedonia DIAbetes Mellitus (CALDIA) Study Group.’, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 22(9), pp. 927–34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9756254 (Accessed: 16 June 2018).

Dhindsa, S. et al. (2004a) ‘Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes’, The Journal of Clinical Endocrinology & Metabolism, 89(11), pp. 5462–5468. doi: 10.1210/jc.2004-0804.

Dhindsa, S. et al. (2004b) ‘Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes’, The Journal of Clinical Endocrinology & Metabolism, 89(11), pp. 5462–5468. doi: 10.1210/jc.2004-0804.

Dhindsa, S. et al. (2004c) ‘Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes’, The Journal of Clinical Endocrinology & Metabolism, 89(11), pp. 5462–5468. doi: 10.1210/jc.2004-0804.

Dhindsa, S. et al. (2016a) ‘Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.’, Diabetes care. American Diabetes Association, 39(1), pp. 82–91. doi: 10.2337/dc15-1518.

Dhindsa, S. et al. (2016b) ‘Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes.’, Diabetes care. American Diabetes Association, 39(1), pp. 82–91. doi: 10.2337/dc15-1518.

Ding, E. L. et al. (2006) ‘Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes’, JAMA, 295(11), p. 1288. doi: 10.1001/jama.295.11.1288.

Ding, E. L. et al. (2009) ‘Sex Hormone–Binding Globulin and Risk of Type 2 Diabetes in Women and Men’, New England Journal of Medicine, 361(12), pp. 1152–1163. doi: 10.1056/NEJMoa0804381.

von Eckardstein, A., Schulte, H. and Assmann, G. (2000) ‘Risk for Diabetes Mellitus in Middle-Aged Caucasian Male Participants of the PROCAM Study: Implications for the Definition of Impaired Fasting Glucose by the American Diabetes Association’, The Journal of Clinical Endocrinology & Metabolism, 85(9), pp. 3101–3108. doi: 10.1210/jcem.85.9.6773.

Fraietta, R., Zylberstejn, D. S. and Esteves, S. C. (2013) ‘Hypogonadotropic hypogonadism revisited.’, Clinics (Sao Paulo, Brazil). Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, 68 Suppl 1(Suppl 1), pp. 81–8. doi: 10.6061/CLINICS/2013(SUP01)09.

Frederiksen, L. et al. (2012) ‘Testosterone therapy increased muscle mass and lipid oxidation in aging men’, AGE. Springer Netherlands, 34(1), pp. 145–156. doi: 10.1007/s11357-011-9213-9.

Ganesh, H. et al. (2009) ‘Prevalence of Hypogonadism in Patients with Type 2 Diabetes Mellitus in an Asian Indian Study Group’, Endocrine Practice, 15(6), pp. 513–520. doi: 10.4158/EP09035.ORR.

Gatling, W. et al. (2001) ‘The Poole Diabetes Study: how many cases of Type 2 diabetes are diagnosed each year during normal health care in a defined community?’, Diabetes research and clinical practice, 53(2), pp. 107–12. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11403859 (Accessed: 16 June 2018).

Ghanim, H. et al. (2007) ‘Role of inflammatory mediators in the suppression of insulin receptor phosphorylation in circulating mononuclear cells of obese subjects’, Diabetologia, 50(2), pp. 278–285. doi: 10.1007/s00125-006-0508-9.

Gianatti, E. J. et al. (2014) ‘Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial.’, Diabetes care. American Diabetes Association, 37(8), pp. 2098–107. doi: 10.2337/dc13-2845.

Grossmann, M. et al. (2008) ‘Low Testosterone Levels Are Common and Associated with Insulin Resistance in Men with Diabetes’, The Journal of Clinical Endocrinology & Metabolism, 93(5), pp. 1834–1840. doi: 10.1210/jc.2007-2177.

Grossmann, M. et al. (2015) ‘Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials’, Clinical Endocrinology. Wiley/Blackwell (10.1111), 83(3), pp. 344–351. doi: 10.1111/cen.12664.

Guay, A. T. et al. (2003) ‘AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE EVALUATION AND TREATMENT OF MALE SEXUAL DYSFUNCTION: A COUPLE’S PROBLEM-2003 UPDATE’, Endocrine Practice, 9(1), pp. 77–95. doi: 10.4158/EP.9.1.77.

Hackett, G. et al. (2014) ‘Testosterone Replacement Therapy Improves Metabolic Parameters in Hypogonadal Men with Type 2 Diabetes but Not in Men with Coexisting Depression: The BLAST Study’, The Journal of Sexual Medicine. Wiley/Blackwell (10.1111), 11(3), pp. 840–856. doi: 10.1111/jsm.12404.

Haffner, S. M. et al. (1996) ‘Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial.’, American journal of epidemiology, 143(9), pp. 889–97. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8610702 (Accessed: 21 June 2018).

Haider, A. et al. (2009) ‘Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men’, Andrologia, 41(1), pp. 7–13. doi: 10.1111/j.1439-0272.2008.00880.x.

Hamdan, F. B. and Al-Matubsi, H. Y. (2009) ‘Assessment of erectile dysfunction in diabetic patients’, International Journal of Andrology, 32(2), pp. 176–185. doi: 10.1111/j.1365-2605.2008.00873.x.

Harman, S. M. (2001) ‘Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men’, Journal of Clinical Endocrinology & Metabolism, 86(2), pp. 724–731. doi: 10.1210/jc.86.2.724.

Heufelder, A. E. et al. (2009) ‘Fifty-two-Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone’, Journal of Andrology. Wiley-Blackwell, 30(6), pp. 726–733. doi: 10.2164/jandrol.108.007005.

Higgins, J. P. T. et al. (2011) ‘The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials.’, BMJ (Clinical research ed.). British Medical Journal Publishing Group, 343, p. d5928. doi: 10.1136/BMJ.D5928.

Hofstra, J. et al. (2008) ‘High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment.’, The Netherlands journal of medicine, 66(3), pp. 103–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18349465 (Accessed: 4 May 2018).

Ibáñez, J. et al. (2008) ‘Lower muscle strength gains in older men with type 2 diabetes after resistance training’, Journal of Diabetes and its Complications, 22(2), pp. 112–118. doi: 10.1016/j.jdiacomp.2007.06.008.

Isidori, A. M. et al. (1999) ‘Leptin and Androgens in Male Obesity: Evidence for Leptin Contribution to Reduced Androgen Levels ¹’, The Journal of Clinical Endocrinology & Metabolism. Oxford University Press, 84(10), pp. 3673–3680. doi: 10.1210/jcem.84.10.6082.

Isidori, A. M. et al. (2005) ‘Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis’, Clinical Endocrinology, 63(3), pp. 280–293. doi: 10.1111/j.1365-2265.2005.02339.x.

Iso, H. et al. (1991) ‘The relation of body fat distribution and body mass with haemoglobin A1c, blood pressure and blood lipids in urban Japanese men.’, International journal of epidemiology, 20(1), pp. 88–94. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2066249 (Accessed: 19 June 2018).

Issa, M. M. et al. (2006) ‘An assessment of the diagnosed prevalence of diseases in men 50 years of age or older.’, The American journal of managed care, 12(4 Suppl), pp. S83-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16551206 (Accessed: 16 June 2018).

Jang, Y. et al. (2001) ‘Differences in body fat distribution and antioxidant status in Korean men with cardiovascular disease with or without diabetes’, The American Journal of Clinical Nutrition, 73(1), pp. 68–74. doi: 10.1093/ajcn/73.1.68.

Jones, T. H. et al. (2011) ‘Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).’, Diabetes care. American Diabetes Association, 34(4), pp. 828–37. doi: 10.2337/dc10-1233.

Jones, T. H. et al. (2011) ‘Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes and/or Metabolic Syndrome (the TIMES2 Study)’, Diabetes Care, 34(4), pp. 828–837. doi: 10.2337/dc10-1233.

Jungwirth, A. et al. (2012) ‘European Association of Urology Guidelines on Male Infertility: The 2012 Update’, European Urology, 62(2), pp. 324–332. doi: 10.1016/j.eururo.2012.04.048.

Kalinchenko, S. Y. et al. (2010) ‘Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study’, Clinical Endocrinology, 73(5), pp. 602–612. doi: 10.1111/j.1365-2265.2010.03845.x.

Kapoor, D. et al. (2005) ‘Androgens, insulin resistance and vascular disease in men’, Clinical Endocrinology, 63(3), pp. 239–250. doi: 10.1111/j.1365-2265.2005.02299.x.

Kapoor, D. et al. (2006) ‘Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes’, European Journal of Endocrinology, 154(6), pp. 899–906. doi: 10.1530/eje.1.02166.

Kapoor, D. et al. (2007) ‘Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity.’, Diabetes care. American Diabetes Association, 30(4), pp. 911–7. doi: 10.2337/dc06-1426.

Kapoor, D. et al. (2007a) ‘Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity’, Diabetes Care, 30(4), pp. 911–917. doi: 10.2337/dc06-1426.

Kapoor, D. et al. (2007b) ‘Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes: Correlations with bioavailable testosterone and visceral adiposity’, Diabetes Care, 30(4), pp. 911–917. doi: 10.2337/dc06-1426.

Kapoor, D. et al. (2007) ‘The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes’, European Journal of Endocrinology, 156(5), pp. 595–602. doi: 10.1530/EJE-06-0737.

Laaksonen, D. E. et al. (2004a) ‘Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.’, Diabetes care, 27(5), pp. 1036–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15111517 (Accessed: 12 June 2018).

Laaksonen, D. E. et al. (2004b) ‘Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.’, Diabetes care, 27(5), pp. 1036–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15111517 (Accessed: 21 June 2018).

Lee, C.-H. et al. (2005) ‘The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics.’, Endocrine research, 31(2), pp. 139–48. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16353672 (Accessed: 15 June 2018).

Leifke, E. et al. (2000) ‘Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort.’, Clinical endocrinology, 53(6), pp. 689–95. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11155090 (Accessed: 19 June 2018).

Li, C. et al. (2010) ‘Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men.’, Diabetes care. American Diabetes Association, 33(7), pp. 1618–24. doi: 10.2337/dc09-1788.

Luconi, M. et al. (2013) ‘Determinants of testosterone recovery after bariatric surgery: is it only a matter of reduction of body mass index?’, Fertility and Sterility, 99(7), p. 1872–1879.e1. doi: 10.1016/j.fertnstert.2013.02.039.

Mammi, C. et al. (2012) ‘Androgens and adipose tissue in males: a complex and reciprocal interplay.’, International journal of endocrinology. Hindawi, 2012, p. 789653. doi: 10.1155/2012/789653.

Mårin, P. et al. (1993) ‘Androgen Treatment of Abdominally Obese Men’, Obesity Research. Wiley-Blackwell, 1(4), pp. 245–251. doi: 10.1002/j.1550-8528.1993.tb00618.x.

Mogri, M. et al. (2013) ‘Testosterone concentrations in young pubertal and post-pubertal obese males.’, Clinical endocrinology. NIH Public Access, 78(4), pp. 593–9. doi: 10.1111/cen.12018.

Moher, D. et al. (2010) ‘Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement’, International Journal of Surgery, 8(5), pp. 336–341. doi: 10.1016/j.ijsu.2010.02.007.

Mokdad, A. H. et al. (2003) ‘Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.’, JAMA, 289(1), pp. 76–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12503980 (Accessed: 24 June 2018).

Muller, M. et al. (2003) ‘Endogenous sex hormones in men aged 40-80 years.’, European journal of endocrinology, 149(6), pp. 583–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14641001 (Accessed: 19 June 2018).

Mulligan, T. et al. (2006) ‘Prevalence of hypogonadism in males aged at least 45 years: the HIM study.’, International journal of clinical practice. Wiley-Blackwell, 60(7), pp. 762–9. doi: 10.1111/j.1742-1241.2006.00992.x.

Muraleedharan, V. et al. (2013) ‘Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes.’, European journal of endocrinology. European Society of Endocrinology, 169(6), pp. 725–33. doi: 10.1530/EJE-13-0321.

Nieschlag, E. et al. (2004) ‘Testosterone replacement therapy: current trends and future directions’, Human Reproduction Update, 10(5), pp. 409–419. doi: 10.1093/humupd/dmh035.

Oh, J. et al. (no date) ‘Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study’, Am Diabetes Assoc. Available at: http://care.diabetesjournals.org/content/25/1/55.short (Accessed: 27 April 2018).

Paul Chubb, S. A. et al. (2008) ‘Lower sex hormone-binding globulin is more strongly associated with metabolic syndrome than lower total testosterone in older men: the Health in Men Study’, European Journal of Endocrinology, 158(6), pp. 785–792. doi: 10.1530/EJE-07-0893.

Perry, J. R. B. et al. (2010) ‘Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes’, Human Molecular Genetics, 19(3), pp. 535–544. doi: 10.1093/hmg/ddp522.

Phillips, G. B. (1984) ‘Evidence for hyperestrogenemia as the link between diabetes mellitus and myocardial infarction.’, The American journal of medicine, 76(6), pp. 1041–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6731462 (Accessed: 16 June 2018).

Pitteloud, N. et al. (2005a) ‘Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men.’, Diabetes care, 28(7), pp. 1636–42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15983313 (Accessed: 16 June 2018).

Pitteloud, N. et al. (2005b) ‘Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men.’, Diabetes care, 28(7), pp. 1636–42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15983313 (Accessed: 15 June 2018).

Rhoden, E. L. et al. (2005) ‘Diabetes mellitus is associated with subnormal serum levels of free testosterone in men’, BJU International, 96(6), pp. 867–870. doi: 10.1111/j.1464-410X.2005.05728.x.

Russell, S. H. et al. (2008) ‘The In Vitro Role of Tumour Necrosis Factor-Alpha and Interleukin-6 in the Hypothalamic-Pituitary Gonadal Axis’, Journal of Neuroendocrinology. Wiley/Blackwell (10.1111), 13(3), pp. 296–301. doi: 10.1046/j.1365-2826.2001.00632.x.

Saad, F. and Gooren, L. J. (2011) ‘The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.’, Journal of obesity. Hindawi, 2011. doi: 10.1155/2011/471584.

Saboor Aftab, S. A., Kumar, S. and Barber, T. M. (2013) ‘The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism’, Clinical Endocrinology, 78(3), pp. 330–337. doi: 10.1111/cen.12092.

Salam, R., Kshetrimayum, A. S. and Keisam, R. (2012) ‘Testosterone and metabolic syndrome: The link.’, Indian journal of endocrinology and metabolism. Wolters Kluwer -- Medknow Publications, 16 Suppl 1(Suppl1), pp. S12-9. doi: 10.4103/2230-8210.94248.

Sattler, F. et al. (2014) ‘Testosterone Supplementation Improves Carbohydrate and Lipid Metabolism in Some Older Men with Abdominal Obesity.’, Journal of gerontology & geriatric research. NIH Public Access, 3(3), p. 1000159. doi: 10.4172/2167-7182.1000159.

Seftel, A. (2006) ‘Male hypogonadism. Part II: etiology, pathophysiology and diagnosis’, International Journal of Impotence Research, 18(3), pp. 223–228. doi: 10.1038/sj.ijir.3901365.

Selvin, E. et al. (2007) ‘Androgens and Diabetes in Men: Results from the Third National Health and Nutrition Examination Survey (NHANES III)’, Diabetes Care, 30(2), pp. 234–238. doi: 10.2337/dc06-1579.

Semple, C. G., Gray, C. E. and Beastall, G. H. (1988) ‘Androgen levels in men with diabetes mellitus.’, Diabetic medicine : a journal of the British Diabetic Association, 5(2), pp. 122–5. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2964976 (Accessed: 16 June 2018).

Shahwan, M. M. et al. (1978) ‘Differences in pituitary and testicular function between diabetic patients on insulin and oral anti-diabetic agents.’, Diabetologia, 15(1), pp. 13–7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/98378 (Accessed: 16 June 2018).

Simon, D. et al. (1997) ‘Association between Plasma Total Testosterone and Cardiovascular Risk Factors in Healthy Adult Men: The Telecom Study ¹’, The Journal of Clinical Endocrinology & Metabolism, 82(2), pp. 682–685. doi: 10.1210/jcem.82.2.3766.

Small, M. et al. (1987) ‘Oestradiol levels in diabetic men with and without a previous myocardial infarction.’, The Quarterly journal of medicine, 64(243), pp. 617–23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3671665 (Accessed: 16 June 2018).

Svartberg, J. et al. (2004) ‘Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study.’, European journal of endocrinology, 150(1), pp. 65–71. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14713281 (Accessed: 16 June 2018).

Svartberg, J. et al. (2004) ‘The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromsø Study.’, Diabetes & metabolism, 30(1), pp. 29–34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15029095 (Accessed: 19 June 2018).

Tajar, A. et al. (2010) ‘Characteristics of Secondary, Primary, and Compensated Hypogonadism in Aging Men: Evidence from the European Male Ageing Study’, The Journal of Clinical Endocrinology & Metabolism, 95(4), pp. 1810–1818. doi: 10.1210/jc.2009-1796.

Tibblin, G. et al. (1996) ‘The pituitary-gonadal axis and health in elderly men: a study of men born in 1913.’, Diabetes, 45(11), pp. 1605–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8866567 (Accessed: 16 June 2018).

Tomar, R. et al. (2006) ‘Contrasting testosterone concentrations in type 1 and type 2 diabetes.’, Diabetes care. American Diabetes Association, 29(5), pp. 1120–2. doi: 10.2337/diacare.2951120.

Traish, A. M., Saad, F. and Guay, A. (2008) ‘The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance’, Journal of Andrology, 30(1), pp. 23–32. doi: 10.2164/jandrol.108.005751.

Tripathy, D. et al. (1998) ‘Effect of Testosterone Replacement on Whole Body Glucose Utilisation and Other Cardiovascular Risk Factors in Males with Idiopathic Hypogonadotrophic Hypogonadism’, Hormone and Metabolic Research. © Georg Thieme Verlag Stuttgart · New York, 30(10), pp. 642–645. doi: 10.1055/s-2007-978950.

Wang, J.-X. (2009) ‘[To standardize the stratified therapy of postremission after induction therapy in adult acute myeloid leukemia patients].’, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 30(1), pp. 1–2. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19563025 (Accessed: 16 June 2018).

Watanobe, H. and Hayakawa, Y. (2003) ‘Hypothalamic Interleukin-1β and Tumor Necrosis Factor-α, But Not Interleukin-6, Mediate the Endotoxin-Induced Suppression of the Reproductive Axis in Rats’, Endocrinology, 144(11), pp. 4868–4875. doi: 10.1210/en.2003-0644.

Wild, S. et al. (2004) ‘Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.’, Diabetes care, 27(5), pp. 1047–53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15111519 (Accessed: 1 July 2018).

Wu, F. C. W. et al. (2010a) ‘Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men’, New England Journal of Medicine. Massachusetts Medical Society , 363(2), pp. 123–135. doi: 10.1056/NEJMoa0911101.

Wu, F. C. W. et al. (2010b) ‘Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men’, New England Journal of Medicine. Massachusetts Medical Society , 363(2), pp. 123–135. doi: 10.1056/NEJMoa0911101.

Yeap, B. B. et al. (2009) ‘Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study.’, European journal of endocrinology. European Society of Endocrinology, 161(4), pp. 591–8. doi: 10.1530/EJE-09-0348.

Yialamas, M. A. et al. (2007) ‘Acute Sex Steroid Withdrawal Reduces Insulin Sensitivity in Healthy Men with Idiopathic Hypogonadotropic Hypogonadism’, The Journal of Clinical Endocrinology & Metabolism. Oxford University Press, 92(11), pp. 4254–4259. doi: 10.1210/jc.2007-0454.

Zietz et al. (2000) ‘Association of increased C-peptide serum levels and testosterone in type 2 diabetes.’, European journal of internal medicine, 11(6), pp. 322–328. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11113656 (Accessed: 16 June 2018).

Zumoff, B., Miller, L. K. and Strain, G. W. (2003) ‘Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone.’, Metabolism: clinical and experimental, 52(9), pp. 1126–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14506617 (Accessed: 8 June 2018).